Acarbose vs Retatrutide
A side-by-side research comparison of Acarbose and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acarbose | Retatrutide |
|---|---|---|
| Full name | Acarbose (Alpha-Glucosidase Inhibitor) | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | FDA-approved drug | Phase 3 Clinical Trial |
| Mechanism | Inhibits intestinal alpha-glucosidase enzymes, slowing the breakdown of complex carbohydrates into glucose. This flattens post-prandial glucose and insulin excursions and shifts undigested carbohydrate to the colon, feeding beneficial short-chain-fatty-acid-producing bacteria. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 645.6 Da | 5,200 Da (approximate) |
| Half-life | ~2 hours | 6 days |
| Bioavailability | Very low systemic (~2%); acts locally in the gut | High (SubQ) |
| Typical dose | 25-100 mg per meal | 1-2 mg → titrate up to 12 mg |
| Frequency | With carbohydrate-containing meals | Once weekly |
| Route | Oral tablet | Subcutaneous injection |
Acarbose reported benefits
- Flattens post-meal glucose spikes
- Improves glycemic variability
- Longevity signal (ITP data)
- Feeds beneficial gut bacteria
- Modest weight support
- Minimal systemic absorption
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.